MD Anderson and Myriad Genetics Partner on MRD Assay Development
Myriad Genetics and MD Anderson Cancer Center are partnering to advance the development of a molecular residual disease (MRD) assay.
Read MorePosted by Andy Lundin | Jan 8, 2025 | Molecular Diagnostics |
Myriad Genetics and MD Anderson Cancer Center are partnering to advance the development of a molecular residual disease (MRD) assay.
Read MorePosted by Andy Lundin | Jan 3, 2025 | Swabs |
The nasal swab test accurately diagnoses asthma endotypes, enabling more precise treatments and advancing research into asthma subtypes.
Read MorePosted by Andy Lundin | Dec 30, 2024 | Colorectal |
Mainz Biomed is collaborating with Quest Diagnostics to support the commercialization and FDA validation of a stool-based DNA test.
Read MorePosted by Chris Wolski | Dec 27, 2024 | Lung Cancer |
The Nu.Q Cancer Test distinguished between malignant and benign pulmonary nodules detected by LDCT scans in suspected lung cancer.
Read MorePosted by Chris Wolski | Dec 26, 2024 | Pancreatic |
ClearNote Health collaborates with research teams in Southampton, UK, to use their Avantect Pancreatic Cancer Test in a large-scale study.
Read More